Bankinter (0H7O)
London Exchange · UK · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 15.08 |
|---|---|
| 52-week range | 11.99 – 17.01 |
| Return, 1 month / 3 months | −9.8% / −4.1% |
| Return, 1 year / 3 years | +17.9% / +175.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 32 |
| Volatility (1 year) | 24.3% |
| Worst drawdown (1 year) | -12.5% |
| Average daily value traded | 10.01M EUR |
| Dividend yield | 3.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bankinter is a Spanish bank based in Madrid that serves individual customers, self-employed people and small and medium-sized businesses. It offers current and savings accounts, mortgages, consumer loans, credit cards and investment products, along with private banking and insurance services. Its commercial banking business focuses on Spain, and it also runs a consumer finance operation in other European markets. The bank earns income mainly from lending and from fees on the services it provides to its retail and business customers.
The shares are listed on the London Exchange in UK under the code 0H7O, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bankinter (0H7O) trades on the London Exchange in UK. It last closed at EUR 15.08 on 19 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 438 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 17.9% and over the last three months it fell 4.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 67 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 2.1% | ||
| From 52-week high | -11.2% | ||
| Momentum | 58 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -4.1% | ||
| 6-month return | 3.7% | ||
| 12-month return, skipping the last month | 30.7% | ||
| Risk (lower is better) | 84 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility (1 year) | 24.3% | ||
| Worst drawdown (1 year) | -12.5% | ||
| Liquidity | 74 · Strong | Trades actively. | |
| Average daily value traded | 10.01M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 79 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 3.3% | ||
| Years with dividends | 6 |
Strengths
- Risk (lower is better): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −1.3% |
|---|---|
| 1 month | −9.8% |
| 3 months | −4.1% |
| 6 months | +3.7% |
| 1 year | +17.9% |
| 3 years | +175.1% |
| 5 years | +268.9% |
Signals
| 50-day / 200-day average | 16.34 / 14.76 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.30 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 Jun 2026 | EUR 0.1304 |
| 31 Mar 2026 | EUR 0.1255 |
| 28 Nov 2025 | EUR 0.2440 |
| 23 Jun 2025 | EUR 0.1217 |
| 1 Apr 2025 | EUR 0.1000 |
| 28 Nov 2024 | EUR 0.2390 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.